NCT07203053 - A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2026

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Extensive Stage Lung Small Cell Cancer

Interventions

DRUG

Tarlatamab

"Protocol treatment consists of tarlatamab, administered as an intravenous (i.v.) infusion:~* 1 mg on day 1 (C1D1),~* 10 mg on day 8 (C1D8) and~* 10 mg on day 15 (C1D15),~* then 10 mg every two weeks (Q2W) until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first."